Oxford Pharmascience Group PLC Notice of Interim Results (1679Z)

TIDMOXP

RNS Number : 1679Z

Oxford Pharmascience Group PLC

16 September 2015

Oxford Pharmascience Group plc

("Oxford Pharmascience" or the "Company")

Notice of Results

Oxford Pharmascience, the specialty pharmaceutical company that redevelops medicines to make them better, safer and easier to take, will announce its unaudited interim results for the six months to 30 June 2015, on Tuesday 22 September 2015.

For further information:

Oxford Pharmascience Group Plc

   Marcelo Bravo, Chief Executive                      +44 20 7554 5875

N+1 Singer

   Aubrey Powell / Jen Boorer                             +44 20 7496 3000

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc uses a range of proprietary technology platforms to re-develop existing medicines to make them better, safer or easier to take. The Company does not manufacture or sell its own pharmaceutical products direct to consumers but instead seeks to license its technologies and dossiers to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios.

Oxford Pharmascience Group Plc focuses on existing medicines that are proven to be safe and effective but nevertheless still have associated issues and side effects often affecting compliance. By working with such medicines the Company is able to develop new innovative products for a fraction of the cost, in much quicker timescales and without the high risk of failure associated with developing new drugs.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORVELFFEKFLBBX

(END) Dow Jones Newswires

September 16, 2015 02:01 ET (06:01 GMT)

Grafico Azioni Oxford Nutrascience (LSE:ONG)
Storico
Da Mag 2024 a Giu 2024